Roche’s Susvimo Approved by FDA for Diabetic Retinopathy

Roche’s Susvimo approved by FDA for diabetic retinopathy

Genentech gains FDA approval for diabetic retinopathy treatment

This decision marks the injection as the first and only approved continuous delivery treatment by the FDA capable of maintaining vision in DR patients, with a refill required The post Genentech gains FDA approval for diabetic retinopathy treatment appeared first on Pharmaceutical Business review.

FDA Approves Ranibizumab Injection for Treatment of Diabetic Retinopathy

Ranibizumab injection (Susvimo; Genentech) could offer long-lasting vision preservation and reduce the need for frequent injections in patients with diabetic retinopathy.

FDA Expands Approval of Susvimo to Treat Diabetic Retinopathy

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ranibizumab, is delivered through an ocular implant that is refilled every nine months.

FDA Approves Genentech’s Susvimo for Diabetic Retinopathy

Genentech has received FDA approval for Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR). The approval makes Susvimo the first and only FDA-approved continuous delivery treatment shown to maintain vision in people with DR with one refill every 9 months. Susvimo is now available to US retina specialists and their patients with DR who have previously responded to at least two anti-vascular endothelial growth…

FDA expands Susvimo’s indications to include diabetic retinopathy

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months